Living evidence page · Drugs & supplements
Rapamycin
The 48-week PEARL trial reported a null primary visceral-fat outcome, exploratory signals and substantial limits. It did not show longer healthspan or lifespan.
Safety and regulatory context: Healthy-aging use is off-label. Sirolimus is an immunosuppressant; risks include infection, malignancy, metabolic effects, impaired wound healing and drug interactions.
Compare coverage
Three different evidence questions
Counts and order describe what More Years has released. They do not indicate evidence strength, efficacy, safety, importance, popularity or recommendation.
Released reporting
What the covered evidence says
Small randomized trial · Human outcomes · small randomized trial
PEARL trial found no change in its main visceral-fat outcome
- Population
- 129 adults age 50–85 enrolled; 114 completers included in the published analysis
- Measured
- visceral fat, body composition, biomarkers, surveys and safety
The 48-week randomized trial reported a null primary outcome, exploratory signals and substantial limits on broader healthy-aging claims.
Does not establish: PEARL trial found no change in its main visceral-fat outcome
Published 2026-07-31 · verified 2026-07-31
Primary publications and governing syntheses
1 covered study
These records preserve identifiers, populations, outcomes and interpretation boundaries from the released evidence library.
Other human evidence · peer-reviewed
Pearl Results
DOI: 10.18632/aging.206235
- Population
- humans
- Measured
- visceral fat, body composition, biomarkers, surveys and safety
- Result in released coverage
- The 48-week randomized trial reported a null primary outcome, exploratory signals and substantial limits on broader healthy-aging claims.
- Evidence maturity
- Maturity described in linked reporting
- Funding / conflicts
- Funding and conflict context is retained in linked reporting; this source record does not separately structure it.
- Limitations
- See the linked story for study-specific limitations and applicability boundaries.
The measured result does not establish a general longevity benefit beyond the population, design and outcomes reported.
Verified 2026-07-31 · correction state: not separately structured
Registry records
1 connected clinical trial
Status and results availability are kept separate from evidence conclusions.
Completed · Peer-reviewed publication linked
rapamycin — NCT04488601
- Population
- 129 adults age 50–85 enrolled; 114 completers included in the published analysis
- Intervention / comparator
- small randomized trial
- Primary outcome
- visceral fat, body composition, biomarkers, surveys and safety
- Sponsor / funding context
- Funding and conflict context is source-reviewed in the linked article; registry sponsorship alone is not evidence of benefit.
Registry status is operational information, not evidence of benefit.
Status checked 2026-07-31 · registry link checked 2026-08-27
Coverage timeline
When this reporting was released
- PEARL trial found no change in its main visceral-fat outcomeHuman outcomes · small randomized trial